Article ; Online: Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases.
2024 Volume 100, Issue 1183, Page(s) 334–341
Abstract: Purpose: We evaluated the preference, patient satisfaction, and efficacy of zoledronic acid compared with oral bisphosphonates (BPs) for glucocorticoid-induced osteoporosis (GIOP) in patients with autoimmune diseases.: Methods: We enrolled 50 ... ...
Abstract | Purpose: We evaluated the preference, patient satisfaction, and efficacy of zoledronic acid compared with oral bisphosphonates (BPs) for glucocorticoid-induced osteoporosis (GIOP) in patients with autoimmune diseases. Methods: We enrolled 50 patients with new fractures or osteoporosis detected on follow-up bone densitometry after at least 1 year of oral BP use among patients diagnosed with GIOP during treatment for autoimmune diseases. After 1 year of zoledronic acid treatment, patients completed a survey for preference and satisfaction assessment. Treatment efficacy was analysed by comparing bone mineral density changes and fractures with those in a control group of patients who continued oral BP use. Results: Age, sex, treatment duration, and medication history did not differ significantly between the two groups. Among the participants, 86.7% preferred and were more satisfied with intravenous zoledronic acid than with oral BPs, primarily because of the convenience of its administration interval. Only two patients (4%) reported infusion-related adverse events with zoledronic acid. Furthermore, no significant differences were observed in the annualized percentage change in the bone mineral density of the lumbar spine, femur neck, and hip between patients receiving zoledronic acid and those receiving oral BPs. The occurrence of new fractures was consistent across both groups, with two cases in each, showing no significant differences. Conclusion: Patients showed a preference for and greater satisfaction with zoledronic acid, and its efficacy in treating osteoporosis was comparable to that of oral BPs. Therefore, zoledronic acid is a suitable treatment option for GIOP in patients with autoimmune diseases. |
---|---|
MeSH term(s) | Humans ; Zoledronic Acid/therapeutic use ; Zoledronic Acid/adverse effects ; Osteoporosis/drug therapy ; Osteoporosis/chemically induced ; Female ; Glucocorticoids/adverse effects ; Glucocorticoids/administration & dosage ; Glucocorticoids/therapeutic use ; Male ; Bone Density Conservation Agents/therapeutic use ; Bone Density Conservation Agents/adverse effects ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/chemically induced ; Middle Aged ; Patient Preference ; Bone Density/drug effects ; Aged ; Administration, Oral ; Diphosphonates/therapeutic use ; Diphosphonates/adverse effects ; Diphosphonates/administration & dosage ; Patient Satisfaction ; Treatment Outcome ; Imidazoles/adverse effects ; Imidazoles/therapeutic use ; Imidazoles/administration & dosage |
Chemical Substances | Zoledronic Acid (6XC1PAD3KF) ; Glucocorticoids ; Bone Density Conservation Agents ; Diphosphonates ; Imidazoles |
Language | English |
Publishing date | 2024-01-31 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 80325-x |
ISSN | 1469-0756 ; 0032-5473 |
ISSN (online) | 1469-0756 |
ISSN | 0032-5473 |
DOI | 10.1093/postmj/qgae003 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ua VI Zs.340: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.